Regulatory Update: GSK and Theravance Announce Intention to File Relvar(R) Ellipta(R) for COPD in Japan

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/24/15 -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the intention to file a supplemental Japanese New Drug Application (sJNDA) for Relvar® Ellipta® (fluticasone furoate ...